A Predictive Model Based on Radiomics, Clinical Features, and Pathologic Indicators for Disease-free Survival After Liver Transplantation for Hepatocellular Carcinoma: a 7-year Retrospective Study

Overview

Journal J Gastrointest Oncol

Date 2024 Nov 18

PMID 39554565

Authors

Hao Xie

Bin Shi

Junzhen Fan

Shui Liu

Qiaozhi Ma

Junnan Dai

Siqing Dong

Ying Liu

Han Meng

Hui Liu

Ya Yang

Xuetao Mu

Affiliations

Soon will be listed here.

Abstract

Background: Disease-free survival (DFS) is an essential indicator for evaluating the prognosis of liver transplantation (LT) in hepatocellular carcinoma (HCC) patients. Despite progress in the prediction of DFS by radiomics, only preoperative clinical features have been combined in most studies. The aim of this study was to construct a nomogram model (NM) using preoperative clinical features, radiomics, and postoperative pathological indicators for more effective prediction of DFS.

Methods: This was a retrospective study of a single-center cohort comprising 139 HCC patients. Using the whole cohort, we constructed and assessed a clinical model (CM) based on alpha-fetoprotein (AFP) and alkaline phosphatase (ALP), a pathological model (PM) based on Ki-67 and tumor number, a radiomics model (RM) based on the radiomics score (Rad-score), and an NM based on the above five independent predictors.

Results: Significant correlations between the NM and DFS were observed in the training and validation cohorts. Among the four prediction models, the C-index of the NM was the highest [(training/validation cohort) CM: 0.664/0.676, PM: 0.737/0.691, RM: 0.706/0.697, NM: 0.817/0.760], and the areas under the receiver operating characteristic curves (AUCs) of the NM prediction of 1-year, 2-year, and 3-year DFS were also the highest [(training/validation cohort) 1-year, 2-year, and 3-year CM: 0.726/0.726, 0.685/0.744, 0.645/0.686, PM: 0.789/0.780, 0.801/0.748, 0.841/0.735, RM: 0.769/0.752, 0.717/0.805, 0.748/0.765, NM: 0.882/0.854, 0.867/0.849, 0.882/0.801]. The NM also exhibited the highest net clinical benefit.

Conclusions: Based on radiomics, clinical features, and pathological indicators, the NM could be used to effectively predict DFS after LT in HCC patients, guiding the follow-up and complementary treatment.

References

Shan Q, Hu H, Feng S, Peng Z, Chen S, Zhou Q . CT-based peritumoral radiomics signatures to predict early recurrence in hepatocellular carcinoma after curative tumor resection or ablation. Cancer Imaging. 2019; 19(1):11. PMC: 6391838. DOI: 10.1186/s40644-019-0197-5. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Azoulay D, Audureau E, Bhangui P, Belghiti J, Boillot O, Andreani P . Living or Brain-dead Donor Liver Transplantation for Hepatocellular Carcinoma: A Multicenter, Western, Intent-to-treat Cohort Study. Ann Surg. 2016; 266(6):1035-1044. DOI: 10.1097/SLA.0000000000001986. View

Jin X, Zheng X, Chen D, Jin J, Zhu G, Deng X . Prediction of response after chemoradiation for esophageal cancer using a combination of dosimetry and CT radiomics. Eur Radiol. 2019; 29(11):6080-6088. DOI: 10.1007/s00330-019-06193-w. View

Roberts L, Sirlin C, Zaiem F, Almasri J, Prokop L, Heimbach J . Imaging for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis. Hepatology. 2017; 67(1):401-421. DOI: 10.1002/hep.29487. View

Deng P, Zhao B, Huang X, Xu T, Chen Z, Wei Q . Preoperative contrast-enhanced computed tomography-based radiomics model for overall survival prediction in hepatocellular carcinoma. World J Gastroenterol. 2022; 28(31):4376-4389. PMC: 9453776. DOI: 10.3748/wjg.v28.i31.4376. View

Yeh C, Chen M, Lee W, Jeng L . Prognostic factors of hepatic resection for hepatocellular carcinoma with cirrhosis: univariate and multivariate analysis. J Surg Oncol. 2002; 81(4):195-202. DOI: 10.1002/jso.10178. View

Ortiz-Ramon R, Larroza A, Ruiz-Espana S, Arana E, Moratal D . Classifying brain metastases by their primary site of origin using a radiomics approach based on texture analysis: a feasibility study. Eur Radiol. 2018; 28(11):4514-4523. DOI: 10.1007/s00330-018-5463-6. View

Liu Y, Wei X, Zhang X, Pang C, Xia M, Du Y . CT radiomics combined with clinical variables for predicting the overall survival of hepatocellular carcinoma patients after hepatectomy. Transl Oncol. 2022; 26:101536. PMC: 9483805. DOI: 10.1016/j.tranon.2022.101536. View

10.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

11.

Kim S, Shin J, Kim D, Choi G, Kim M, Choi J . Radiomics on Gadoxetic Acid-Enhanced Magnetic Resonance Imaging for Prediction of Postoperative Early and Late Recurrence of Single Hepatocellular Carcinoma. Clin Cancer Res. 2019; 25(13):3847-3855. DOI: 10.1158/1078-0432.CCR-18-2861. View

12.

Yu M, Chan K, Lee C, Lee Y, Zahr Eldeen F, Chou H . Alkaline phosphatase: does it have a role in predicting hepatocellular carcinoma recurrence?. J Gastrointest Surg. 2011; 15(8):1440-9. DOI: 10.1007/s11605-011-1537-3. View

13.

Gupta S, Bent S, Kohlwes J . Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med. 2003; 139(1):46-50. DOI: 10.7326/0003-4819-139-1-200307010-00012. View

14.

Guzman G, Alagiozian-Angelova V, Layden-Almer J, Layden T, Testa G, Benedetti E . p53, Ki-67, and serum alpha feto-protein as predictors of hepatocellular carcinoma recurrence in liver transplant patients. Mod Pathol. 2005; 18(11):1498-503. DOI: 10.1038/modpathol.3800458. View

15.

Huang Y, Liu Z, He L, Chen X, Pan D, Ma Z . Radiomics Signature: A Potential Biomarker for the Prediction of Disease-Free Survival in Early-Stage (I or II) Non-Small Cell Lung Cancer. Radiology. 2016; 281(3):947-957. DOI: 10.1148/radiol.2016152234. View

16.

Forner A, Llovet J, Bruix J . Hepatocellular carcinoma. Lancet. 2012; 379(9822):1245-55. DOI: 10.1016/S0140-6736(11)61347-0. View

17.

Giannini E, Marenco S, Borgonovo G, Savarino V, Farinati F, Del Poggio P . Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. Hepatology. 2012; 56(4):1371-9. DOI: 10.1002/hep.25814. View

18.

Zheng B, Liu L, Zhang Z, Shi J, Dong L, Tian L . Radiomics score: a potential prognostic imaging feature for postoperative survival of solitary HCC patients. BMC Cancer. 2018; 18(1):1148. PMC: 6249916. DOI: 10.1186/s12885-018-5024-z. View

19.

Liu Z, Yang S, Chen X, Luo C, Feng J, Chen H . Nomogram development and validation to predict Ki-67 expression of hepatocellular carcinoma derived from Gd-EOB-DTPA-enhanced MRI combined with T1 mapping. Front Oncol. 2022; 12:954445. PMC: 9613965. DOI: 10.3389/fonc.2022.954445. View

20.

Hasdemir D, Davila L, Schweitzer N, Meyer B, Koch A, Vogel A . Evaluation of CT vascularization patterns for survival prognosis in patients with hepatocellular carcinoma treated by conventional TACE. Diagn Interv Radiol. 2017; 23(3):217-222. PMC: 5411003. DOI: 10.5152/dir.2016.16006. View